FindTrial
Sign In

A study to assess early seroconversion in accelerated Hepatitis B vaccination in advanced CKD patient.

Assessment of Early Seroconversion by Accelerated Hepatitis B Vaccination in advanced CKD patients- A Randomised Control Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088308
Enrollment
130
Registered
2025-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Hepatitis B Vaccine: Accelerated regimen - 0,1,2,8 weeks Control Intervention1: Hepatitis B Vaccine: Standard regimen - 0,1,2,6 months

Sponsors

Dr Nandhini Devi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 years and above. 2.Patients with advanced CKD with eGFR less than 15 ml/min per 1.73m2. 3.Patients not vaccinated with Hepatitis B vaccine earlier.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of HBV infection. 2.Patients positive for HBsAg. 3.Patients positive for HIV. 4.Recent H/O intake of immunosuppressive drugs. 5.History of allergic adverse effects to other vaccines.

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study was the seroconversion rate at 12 weeks after the first dose of vaccination.Timepoint: The primary outcome of the study was the seroconversion rate at 12 weeks after the first dose of vaccination.—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Edwin Fernando

Stanley Medical College

nephroeddy@gmail.com9597954598

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026